Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 May 2020 | Story Andre Damons | Photo Pexels

A data scientist and research coordinator at the University of the Free State (UFS), in collaboration with his supervisor at the University of Pretoria (UP), is at the forefront of the fight against the Covid-19 virus with accurate data and analysis.
Herkulaas Combrink of the Centre for Teaching and Learning at the UFS and PhD candidate in Computer Science at the UP, said accurate data is important to prevent widespread panic and sensationalism during a global disaster such as the current pandemic. This information helps people to make informed decisions and to reduce their exposure to the threat of the virus.

Assisting decision-makers

“I, along with colleagues from the World Health Organization, the Centers for Disease Control and Prevention in the USA, the provincial office of the Centers for Disease Control and Prevention, provincial clinicians, and the Free State Department of Health led by Dr David Motau, have been able to progress significantly in terms of evidence-based tools to assist provincial and national decision-makers during these turbulent times.”
“It does come at a cost, though, in that we have worked continuously since the lockdown, dedicating all our time and efforts to the department from all over to ensure that we are not part of some of the global statistics we have seen,” said Combrink. 

A paper written together with his supervisor, Dr Vukosi Marivate, has also been accepted by the Department of Higher Education and Training (DHET)-accredited Data Science Journal.  This paper is related to a framework for sharing public data to the public in a way that is useful, usable, and understandable. 

Ongoing projects

Combrink said it is hard to name all those who are/were involved in the great work done by the Free State Department of Health, but some of them include Dr Elizabeth Reji (Head of Department, Family Medicine), Dr Collin Noel (surgeon, senior lecturer at the UFS), Dr Sammy Mokoena (community health registrar, UFS), Dr Ming-Han Motloung (public health medicine specialist, senior lecturer, UFS), Dr Perpetual Chikobvu (Director: Information Management at the Department of Health, affiliated lecturer at the UFS), as well as Alfred Deacon (lecturer at the UFS), who have worked at some point during this short space of time on one of the many projects. 

Some of the projects include the following:

• A provincial database for screening and monitoring.
• A data pipeline and assembly of hospital information flow, liaised with the NICD, Vodacom, and the different district managers to ensure that the pipeline occurs in a timely manner.
• Digitised paper-based capturing tools for rapid data capturing and processing.
• Incorporated state-of-the-art visualisation tools to action data into useful information for decision-makers in certain areas.
• Provided both provincial and national projections, stress testing different scenarios using a variety of statistical, computational, and/or machine-learning approaches to add to the already existing projections of the Council for Scientific and Industrial Research (CSIR).
• Training healthcare professionals in the field to apply these tools within their own districts.
No easy task

“These aforementioned feats were by no means easy and are not completed yet, but we are getting there. In the foreseeable future, I will be working closely with national and international researchers to deploy a tool for hospital managers in the Free State that will assist them when we move from level 5 to any level below.”

“In addition to this, I am constantly providing support to the Free State Department of Health regarding any analysis required for decision-making purposes. The teams we work in comprise highly competent individuals with a passion for solving problems from multidisciplinary perspectives,” according to Combrink.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept